Morvarid Mohseni, Ph.D
Affiliations: | 2009-2013 | Stem Cell & Regenerative Biology | Harvard - Boston Children's Hospital |
Area:
Cell Biology, Oncology, Regenerative Biology, Molecular Pharmacology, Stem Cell Biology,Google:
"Morvarid Mohseni"Mean distance: (not calculated yet)
Parents
Sign in to add mentorAthar Chishti | grad student | 2009 | University of Illinois, Chicago |
Fernando Camargo | post-doc | 2013 | Harvard - Boston Children's Hospital |
Collaborators
Sign in to add collaboratorAdam Bass | collaborator | ||
Stephen C. Blacklow | collaborator | (Chemistry Tree) | |
Reuben Kapur | collaborator | (Cell Biology Tree) | |
Keith L. Ligon | collaborator | ||
Scott R. Manalis | collaborator | (E-Tree) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Wu W, Ishamuddin SH, Quinn TW, et al. (2024) Measuring single-cell density with high throughput enables dynamic profiling of immune cell and drug response from patient samples. Biorxiv : the Preprint Server For Biology |
Amante RJ, Jehanno C, De Silva D, et al. (2023) PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer. Journal of Mammary Gland Biology and Neoplasia. 28: 13 |
Vemulapalli V, Chylek LA, Erickson A, et al. (2021) Time resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling. Elife. 10 |
Wang Y, Mohseni M, Grauel A, et al. (2021) SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. Scientific Reports. 11: 1399 |
Hao HX, Liu C, Lu H, et al. (2020) Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
LaMarche MJ, Acker MG, Argintaru A, et al. (2020) Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry |
Lu H, Liu C, Huynh H, et al. (2020) Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. Oncotarget. 11: 265-281 |
Pandey R, Ramdas B, Wan C, et al. (2019) SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations. The Journal of Clinical Investigation |
Hao HX, Wang H, Liu C, et al. (2019) Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers. Molecular Cancer Therapeutics |
Lu H, Liu C, Velazquez R, et al. (2019) SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors. Molecular Cancer Therapeutics |